Business
BioSpectrum Asia
Fujifilm completes setting up of one of Japan's largest Bio CDMO facilities at Toyama
Fujifilm Corporation has announced the completion of one of Japan's largest bio CDMO facilities (the new plant) at the Toyama Second Factory of Fujifilm Toyama Chemical.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Gene Solutions and Pangea Laboratory establish strategic collaboration for cancer diagnostics
Vietnam headquartered startup Gene Solutions, & US-based Pangea Laboratory, a CLIAcertified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), have announced a strategic collaboration to advance US verification & clinical validation of liquid biopsy assays designed for cancer detection, profiling, & monitoring.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Rakuten Medical and Lotte Biologics ink agreement to support biopharma in oncology
US-based Rakuten Medical, Inc. and South Korea's Lotte Biologics have signed a biopharmaceutical contract manufacturing agreement to strengthen Rakuten Medical's production capabilities for its innovative oncology therapy, Alluminox platformbased photoimmunotherapy.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Retinal Gene Therapy secures regulatory approval in Japan
Nanoscope Therapeutics, Inc., a biotechnology company developing disease-agnostic therapies for vision loss caused by retinal degeneration, has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted both Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations to MCO-010, its lead optogenetic therapy for patients with severe vision loss from inherited retinal dystrophies (IRDS).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Foresee Pharma inks $584.5 M deal with Primevera Therapeutics
Taiwan-based Foresee Pharmaceuticals has announced that Foresee Pharmaceuticals USA Inc., the company's fullyowned US subsidiary, has officially signed an exclusive global licensing agreement with Primevera Therapeutics, LLC for its MMP-12 inhibitor programmes.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
ElpasBio and Fosun Kairos collaborate to commercialise Allo Join stem cell therapy
China-based startup Elpas Bio Holdings has entered into a collaboration agreement with Fosun Kairos for the commercialisation of ElpasBio's investigational allogeneic human adipose-derived mesenchymal stem cell (haMPC) therapy, lotazadromcel (trade name AlloJoin) for the treatment of knee osteoarthritis (KOA) in Mainland China, Hong Kong SAR, and Macau SAR.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Biocon concludes Rs 4,150 Cr equity fundraise through Qualified Institutions Placement
Bengaluru-based Biocon has announced the successful completion of a Qualified Institutions Placement (QIP), raising Rs 4,150 crore ($460 million) through the issuance of 112,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per Equity Share (including a premium of Rs 363.35 per Equity Share).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Hong Kong launches Chinese medicine hospital
A launch ceremony was recently held for the Chinese Medicine Hospital of Hong Kong (CMHHK) and the Government Chinese Medicines Testing Institute (GCMTI).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
The Race to Build Singapore's Biotech Unicorns
MIRXES, known for its work in early cancer detection and backed by A*STAR and the National University of Singapore, became Southeast Asia's first biotech unicorn when it listed on the Hong Kong Exchange in 2025.
5 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
BIRAC inks Letter of Intent with Global Antibiotic Research & Development Partnership
Biotechnology Industry Research Assistance Council (BIRAC), under the Department of Biotechnology (DBT), Government of India, has announced a Letter of Intent (LOI) with the Global Antibiotic Research & Development Partnership (GARDP), a Swiss not-forprofit organisation that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Sky Labs secures European approval for ring-type blood pressure monitor
South Korea based startup Sky Labs has announced that its ring-type blood pressure monitor 'CART PLATFORM,' recently obtained the European Union's Medical Device Regulation (CE-MDR) certification.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
AstraZeneca buys remaining China CAR-T therapy rights from AbelZeta Pharma for $630 M
US-based AbelZeta Pharma, Inc., a global clinicalstage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, has announced that AstraZeneca has agreed to acquire AbelZeta's 50 per cent share of the China development and commercialisation rights to C-CARO31, such that AstraZeneca acquires the sole right to develop, manufacture and commercialise C-CAR031 globally.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Neuroinflammation is not only a hallmark of Alzheimer's disease but a key pathological feature in other neurodegenerative disorders"
As dementia becomes the leading cause of death in Australia and Alzheimer’s disease continues to affect millions worldwide, the urgency for fundamentally new treatment strategies has never been clearer.
4 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
LivsMed completes largest KOSDAQ IPO of 2025, raising w135.9 B
LivsMed, a minimally invasive surgical device company, has completed an initial public offering on Korea’s KOSDAQ market, raising about $94 million ( ₩135.9 billion) at ₩55,000 per share.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Leprosy Isn't Over: South-East Asia's Unfinished Fight
As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.
2 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR"
After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point.
5 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
The Strategic Rise of India's Deep-Science Economy
India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.
4 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Japan strengthening biopharma capabilities
Asia's biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.
7 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Cancer Diagnosis, Accelerated by AI
Cancer remains a leading cause of death worldwide, with Asia bearing a disproportionate burden.
10+ min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Beyond Companion Diagnostics: How Biomarkers and Digital Technologies Will Reshape Oncology Care in Asia by 2026
The oncology landscape in Asia stands at a critical juncture.
5 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Pharma M&A set to boom in 2026
After years of unspectacular Mergers and Acquisitions (M&A) activity, 2025 recorded some of the largest pharma deals.
3 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Seeing Opportunity in Ophthalmology
Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.
6 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Reshaping Asia's Healthcare with mRNA Innovation
The COVID-19 pandemic acted as both a challenge and a catalyst, serving as a testbed that fundamentally reshaped the biotechnology landscape across Asia and beyond. What emerged during this period was not just a breakthrough moment for mRNA, but the early foundation of a broader transformation that is still unfolding.
2 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Momentum in Motion: What Will Shape APAC's Life Sciences Landscape in 2026?
Asia-Pacific's life sciences sector is growing rapidly, driven by its scale, diversity and resilience. Accelerating demographic change and strong investment in innovation position the region to outpace global growth and shape the future of healthcare.
5 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
The Future of mRNA Is Being Built in APAC
Beyond scientific advancement, mRNA represents a strategic opportunity shaped by policy stability, public investment and regional collaboration. Across APAC, governments are increasingly recognising that supportive regulatory frameworks and long-term funding can serve as powerful competitive advantages, attracting global capital and talent. While political dynamics in the United States have slowed momentum, experts emphasise that the science underpinning mRNA technology remains sound. To fully realise its potential, the region will need greater coordination across borders, including regulatory harmonisation and joint development pathways, to build a resilient mRNA ecosystem capable of addressing shared health challenges and driving long-term innovation.
10+ min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
How Precision Medicine Is Reshaping Cancer Care
Despite major advances in cancer detection and treatment, high recurrence rates and progression to advanced disease continue to challenge outcomes across Asia-making precision medicine a critical catalyst for shifting cancer care from disease management toward treat-to-cure. By leveraging molecular insights, biomarker testing and collaborative healthcare ecosystems, precision medicine offers the potential to deliver more effective, personalised and sustainable cancer care for patients across the region.
2 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Repligen introduces next-generation chromatography resins
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has announced the launch of three new high-performance chromatography resins:
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Hanahealth by DSS Imagetech launches GERI Time-Lapse Incubator in India
Hanahealth by DSS Imagetech, the authorised partner of Sydney-based Genea Biomedx, has launched the advanced GERI Time-Lapse Incubator pan India. GERI, the nextgeneration Time Lapse embryo culture system from Genea Biomedx, is ideal for IVF clinics, labs adopting digital transformation, centres working toward accreditation, and research-focused fertility groups as it enables them to modernise their processes and improve IVF outcomes.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Biotechnology to Drive Next Industrial Revolution: Dr Jitendra Singh
\"Biotechnology will play a defining role in shaping the next industrial revolution and will be a key driver of global and Indian economic growth\", said Dr Jitendra Singh, the Union Minister of State (Independent Charge) for Science and Technology.
1 min |
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Cartherics names Dr lan Nisbet as CEO
Australia-based Cartherics, a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programmes in ovarian cancer and endometriosis, has announced the appointment of Dr Ian Nisbet as Chief Executive Officer, as part of a planned leadership transition.
1 min |